Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06389539 · ClinicalTrials.gov registry record · NA

Synbiotic to Attenuate Resorption of the Skeleton

A NA study of Aging and Inflammation, sponsored by Hebrew SeniorLife.

Recruiting
Registry status
NA
Development phase
220
Enrollment target
1
Study location

NCT06389539 is a NA study of Aging and Inflammation that is actively recruiting participants, run by Hebrew SeniorLife. The registered enrollment target is 220 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06389539, a NA study of Aging and Inflammation, is actively recruiting participants, sponsored by Hebrew SeniorLife.

RECRUITING
Registry status
NA
Development phase
220 participants
Enrollment target
1
Study location

Study Summary

This randomized, double blind, placebo controlled clinical trial will test the efficacy of a probiotic/prebiotic combination ("synbiotic") on the skeleton in older women.

Interventions

  • OTHER Placebo
  • OTHER SBD111 medical food

Study Locations (1)

Massachusetts

  • Hebrew SeniorLife - Roslindale

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2024-08-12
Est. Completion 2029-03
Phase NA

Sponsor

Hebrew SeniorLife

32 total trials

What the Registry Record Tells You About NCT06389539

The ClinicalTrials.gov registry entry for NCT06389539 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (90% lower). The listed sponsor is Hebrew SeniorLife, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Aging appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06389539 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06389539 about?

NCT06389539 is a clinical study titled "Synbiotic to Attenuate Resorption of the Skeleton". This randomized, double blind, placebo controlled clinical trial will test the efficacy of a probiotic/prebiotic combination ("synbiotic") on the skeleton in older women.

What is the current status of trial NCT06389539?

This trial is currently recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2024-08-12. Estimated completion is 2029-03.

What conditions does trial NCT06389539 study?

This clinical trial studies the following conditions: Aging, Inflammation, Osteoporosis.

What interventions are being tested in trial NCT06389539?

The interventions under investigation include: Placebo (OTHER), SBD111 medical food (OTHER).

Who is sponsoring clinical trial NCT06389539?

This trial is sponsored by Hebrew SeniorLife, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06389539 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.